Isolation of Circulating Tumor Cells from Glioblastoma Patients by Direct Immunomagnetic Targeting

Lynch, David T.; Powter, Branka; Po, Joseph W.; Cooper, Adam; Garrett, Celine; Koh, Eng‐Siew; Sheridan, Mark; Gelder, James van; Darwish, Basma; McKechnie, Simon; Bazina, Renata; Jaeger, M.; Roberts, Tara L.; Souza, Paul de; Becker, Therese M.

doi:10.3390/app10093338

Cited by 12 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brain cancer, liquid biopsy analysis may be more challenging due to the blood–brain barrier preventing release of tumour derived entities into the blood. Nevertheless, we and others have shown that CTCs and ctDNA can be isolated and analysed from brain cancer patients (Lynch 2020 ; Macarthur et al 2014 ; Müller et al 2014 ; Sareen et al 2020 ; Sullivan et al 2014 ). Further, ctDNA detection could predict the recurrence of disease earlier than conventional methods of monitoring in many cancer types (Ding et al 2019 ; Gao et al 2016 ; McEvoy et al 2019 ; Sozzi et al 2001 ; Tie et al 2016 ; Wang et al 2015 ).…”

Section: Detection Of Tert Promoter Mutations In Lmentioning

confidence: 92%

Human TERT promoter mutations as a prognostic biomarker in glioma

Powter

Jeffreys

Sareen

et al. 2021

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

The TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers including glioblastoma multiforme (GBM), where the prevalence of these mutations is as high as 80%. Additionally, the rs2853669 single nucleotide polymorphism (SNP) may cooperate with these pTERT mutations in modulating progression and overall survival in GBM. Using liquid biopsies, pTERT mutations, C228T and C250T, and other clinically relevant biomarkers can be easily detected with high precision and sensitivity, facilitating longitudinal analysis throughout therapy and aid in cancer patient management.In this review, we explore the potential for pTERT mutation analysis, via liquid biopsy, for its potential use in personalised cancer therapy. We evaluate the relationship between pTERT mutations and other biomarkers as well as their potential clinical utility in early detection, prognostication, monitoring of cancer progress, with the main focus being on brain cancer.

show abstract

Section: Detection Of Tert Promoter Mutations In Lmentioning

confidence: 92%

Human TERT promoter mutations as a prognostic biomarker in glioma

Powter

Jeffreys

Sareen

et al. 2021

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Circulating tumor cells (CTCs) are cells that are released into the bloodstream from primary tumors and metastatic deposits [ 251 ] ( Figure 2 ). In many recent studies, CTCs have been found in the blood of GBM patients [ 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 ]. GBMs discharge CTCs with invasive mesenchymal properties into the bloodstream, revealing mutations that were not observed in the primary tumor [ 256 , 260 ].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Prognostic and Predictive Biomarkers in Gliomas

Śledzińska

Bebyn

Furtak³

et al. 2021

IJMS

131

106

View full text Add to dashboard Cite

Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize the therapeutic approach to the patient and reveal new points of treatment options. Moreover, the 2021 World Health Organization Classification of Tumors of the Central Nervous System has fundamentally changed the classification of gliomas and incorporated many molecular biomarkers. Given the rapid progress in neuro-oncology, here we compile the latest research on prognostic and predictive biomarkers in gliomas. In adult patients, IDH mutations are positive prognostic markers and have the greatest prognostic significance. However, CDKN2A deletion, in IDH-mutant astrocytomas, is a marker of the highest malignancy grade. Moreover, the presence of TERT promoter mutations, EGFR alterations, or a combination of chromosome 7 gain and 10 loss upgrade IDH-wildtype astrocytoma to glioblastoma. In pediatric patients, H3F3A alterations are the most important markers which predict the worse outcome. MGMT promoter methylation has the greatest clinical significance in predicting responses to temozolomide (TMZ). Conversely, mismatch repair defects cause hypermutation phenotype predicting poor response to TMZ. Finally, we discussed liquid biopsies, which are promising diagnostic, prognostic, and predictive techniques, but further work is needed to implement these novel technologies in clinical practice.

show abstract

“…Despite this, several research efforts have been investigating the existence of circulating glial tumor cells (CGTCs) using a variety of methods, with highly variable results. Diagnostic sensitivities were reported between 21%-80% (185)(186)(187)(188)(189)(190)(191)(192). Apart from diagnosis, CGTCs might also have other purposes.…”

Section: Circulating Cells Extracellular Vesicles and Metabolomics Circulating Glioma Cellsmentioning

confidence: 99%

“…Apart from diagnosis, CGTCs might also have other purposes. However, the cells were often not correlated with tumor grade (187,190,192), survival (188) or tumor burden (189) and they could not be used to differentiate between different glial tumor types (187). Interestingly, CGTCs have also been investigated as a tool to differentiate between tumor recurrence and radiation necrosis (192), and to differentiate between pseudoprogression and actual tumor progression (186,190,191), though such applications are definitely not ready for implementation in the current daily clinics.…”

Section: Circulating Cells Extracellular Vesicles and Metabolomics Circulating Glioma Cellsmentioning

confidence: 99%

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

BackgroundGliomas are the most common and aggressive tumors of the central nervous system. A robust and widely used blood-based biomarker for glioma has not yet been identified. In recent years, a plethora of new research on blood-based biomarkers for glial tumors has been published. In this review, we question which molecules, including proteins, nucleic acids, circulating cells, and metabolomics, are most promising blood-based biomarkers for glioma diagnosis, prognosis, monitoring and other purposes, and align them to the seminal processes of cancer.MethodsThe Pubmed and Embase databases were systematically searched. Biomarkers were categorized in the identified biomolecules and biosources. Biomarker characteristics were assessed using the area under the curve (AUC), accuracy, sensitivity and/or specificity values and the degree of statistical significance among the assessed clinical groups was reported.Results7,919 references were identified: 3,596 in PubMed and 4,323 in Embase. Following screening of titles, abstracts and availability of full-text, 262 articles were included in the final systematic review. Panels of multiple biomarkers together consistently reached AUCs >0.8 and accuracies >80% for various purposes but especially for diagnostics. The accuracy of single biomarkers, consisting of only one measurement, was far more variable, but single microRNAs and proteins are generally more promising as compared to other biomarker types.ConclusionPanels of microRNAs and proteins are most promising biomarkers, while single biomarkers such as GFAP, IL-10 and individual miRNAs also hold promise. It is possible that panels are more accurate once these are involved in different, complementary cancer-related molecular pathways, because not all pathways may be dysregulated in cancer patients. As biomarkers seem to be increasingly dysregulated in patients with short survival, higher tumor grades and more pathological tumor types, it can be hypothesized that more pathways are dysregulated as the degree of malignancy of the glial tumor increases. Despite, none of the biomarkers found in the literature search seem to be currently ready for clinical implementation, and most of the studies report only preliminary application of the identified biomarkers. Hence, large-scale validation of currently identified and potential novel biomarkers to show clinical utility is warranted.

show abstract

Isolation of Circulating Tumor Cells from Glioblastoma Patients by Direct Immunomagnetic Targeting

Cited by 12 publications

References 19 publications

Human TERT promoter mutations as a prognostic biomarker in glioma

Human TERT promoter mutations as a prognostic biomarker in glioma

Prognostic and Predictive Biomarkers in Gliomas

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

Contact Info

Product

Resources

About